A Phase 1b/2 Study of the PARP Inhibitor Niraparib in Combination With Trastuzumab in Patients With Metastatic HER2+ Breast Cancer

Trial Profile

A Phase 1b/2 Study of the PARP Inhibitor Niraparib in Combination With Trastuzumab in Patients With Metastatic HER2+ Breast Cancer

Not yet recruiting
Phase of Trial: Phase I/II

Latest Information Update: 31 Jan 2018

At a glance

  • Drugs Niraparib (Primary) ; Trastuzumab (Primary)
  • Indications Breast cancer
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 25 Jan 2018 Planned End Date changed from 2 Jan 2021 to 1 Jun 2021.
    • 25 Jan 2018 Planned primary completion date changed from 2 Jan 2020 to 1 Jun 2020.
    • 25 Jan 2018 Planned initiation date changed from 2 Jan 2018 to 1 Jun 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top